VRDN Earnings Viridian Therapeutics, Inc.De
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–21 of 21
| Q3 2024 | 2024-09-30 | -1.15 | 2024-11-12 | 10-Q |
| Q2 2024 | 2024-06-30 | -1.02 | 2024-08-08 | 10-Q |
| Q1 2024 | 2024-03-31 | -0.79 | 2024-05-08 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -1.34 | 2024-02-27 | 10-K |
| FY 2023 | 2023-12-31 | -5.31 | 2024-02-27 | 10-K |
| Q3 2023 | 2023-09-30 | -1.09 | 2023-11-13 | 10-Q |
| Q2 2023 | 2023-06-30 | -1.27 | 2023-08-08 | 10-Q |
| Q1 2023 | 2023-03-31 | -1.61 | 2023-05-10 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -1.15 | 2023-03-09 | 10-K |
| FY 2022 | 2022-12-31 | -4.05 | 2023-03-09 | 10-K |
| Q3 2022 | 2022-09-30 | -0.86 | 2022-11-14 | 10-Q |
| Q2 2022 | 2022-06-30 | -1.06 | 2022-08-15 | 10-Q |
| Q1 2022 | 2022-03-31 | -0.98 | 2022-05-13 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | -0.29 | 2022-03-11 | 10-K |
| FY 2021 | 2021-12-31 | -6.66 | 2022-03-11 | 10-K |
| Q3 2021 | 2021-09-30 | -1.25 | 2021-11-05 | 10-Q |
| Q2 2021 | 2021-06-30 | -2.21 | 2021-08-12 | 10-Q |
| Q1 2021 | 2021-03-31 | -2.91 | — | — |
| FY 2020 | 2020-12-31 | -31.13 | — | — |
| Q3 2020 | 2020-09-30 | -1.48 | — | — |
| Q2 2020 | 2020-06-30 | -1.82 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.